Objectives: To investigate the relation between metastatic potential of salivary adenoid cystic carcinoma (SACC) and tumor cell-platelet adhesion, and the antimetastatic effect of integrin IIb/IIIa inhibitor on SACC. ...Objectives: To investigate the relation between metastatic potential of salivary adenoid cystic carcinoma (SACC) and tumor cell-platelet adhesion, and the antimetastatic effect of integrin IIb/IIIa inhibitor on SACC. Methods: Tumor cell-platelet adhesion of highly metastatic SACC-LM, non-highly metastatic SACC-83 and effect of aspirin, arginine-aspartate (RD), magnesium acetylsalicylate on adhesion were studiedin vitro. Antimetastafic effect of aspirin, RD, magnesium acetysalicylate on experimental metastasis of SACC was observedin vivo. Results: The tumor cell-platelet adhesion was stronger in SACC-LM than in SACC-83. Aspirin, RD and magnesium acetylsalicylate could inhibit the adhesion of SACC-LM at the concentration of 1, 5 and 25 μg/ml. RD can inhibit experimental metastasis of SACC. Conclusion: Metastasis of SACC is related to platelet-tumor cell adhesion, RD could inhibit metastasis of SACC.展开更多
Objective:To investigate the effect of preoperative bronchial artery infusion chemotherapy on the tumor malignancy of patients with stage IIIA non-small cell lung cancer.Methods:99 patients with stage IIIA non-small c...Objective:To investigate the effect of preoperative bronchial artery infusion chemotherapy on the tumor malignancy of patients with stage IIIA non-small cell lung cancer.Methods:99 patients with stage IIIA non-small cell lung cancer who underwent surgical treatment in our hospital between January 2015 and August 2018 were chosen as the research subjects, and the preoperative adjuvant therapies were reviewed and used to divide them into the control group (n=51) who received conventional neoadjuvant chemotherapy and the study group (n=48) who received neoadjuvant chemotherapy combined with bronchial artery infusion chemotherapy. The differences in the expression levels of NSCLC-related proliferation, invasion and apoptosis genes in intraoperative lesion tissues were compared between the two groups.Results: NSCLC-related proliferation genes CD137L, dlk1, EZH2 and WT1 mRNA expression in lesion tissues of study group were lower than those of control group whereas DCLAK11 mRNA expression was higher than that of control group;NSCLC-related invasion genes ALX1, periostin and RAC1 mRNA expression were lower than those of control group whereas DAL-1 mRNA expression was higher than that of control group;NSCLC-related apoptosis genes Survivin, Livin, bcl-2 and Bag-1 mRNA expression were lower than those of control group.Conclusion: Preoperative bronchial artery infusion chemotherapy can further inhibit the malignant biological behaviors of cancer cells in patients with stage IIIA NSCLC.展开更多
Context: Glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibitors improve myocard ial rep erfusion and clinical outcomes of patients undergoing primary percutaneous coron ary intervention (PCI), but optimal timing of administra...Context: Glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibitors improve myocard ial rep erfusion and clinical outcomes of patients undergoing primary percutaneous coron ary intervention (PCI), but optimal timing of administration remains unclear. No systematic reviews have comprehensively examined the effects of early vs delaye d administration of these agents. Objective: To perform a meta-analysis of ra nd omized trials of early (prior to transfer to the catheterization laboratory) vs late (at the time of PCI) intravenous administration of Gp IIb/IIIa inhibitors i n acute ST-segment elevation myocardial infarction (STEMI). Data Sources: MEDLI NE and the Cochrane Controlled Trials Register search of the literature over the past 10 years; papers presented at major cardiac conferences; consultation with national and international colleagues as well as Gp IIb/IIIa inhibitor drug man ufacturers; and text and journal article bibliographies. Study Selection and Dat a Extraction: We examined trials of randomized comparisons between early adminis tration at the point of initial contact (emergency department or ambulance) and late administration (catheterization laboratory) of Gp IIb/IIIa inhibitors in ST EMI. Outcome data had to be available on both culprit artery patency evaluated b y Thrombolysis in Myocardial Infarction (TIMI) flow grades on admission and mort ality. Two authors independently reviewed abstracts or complete articles. Six st udies met inclusion criteria. Independent data extraction was performed by 2 rev iewers and confirmed by consensus. Data Synthesis: The 6 trials enrolled 931 STEMI patients treated with abciximab (3 trials) or tirofiban (3 trials) in combination with primary P CI. TIMI grade 2 or 3 flow (41.7%<<194/465 vs 29.8%<<139/466>>) as well as TIMI g rade 3 flow (20.3%<<84/ 413>> vs 12.2%<<51/418>>) were significantly more frequent in the early group compared with the late group (odds ratio <<OR>>, 1.69; 95%con fidence interval <<CI>>, 1.28-2.22; P< .001; and OR, 1.85; 95%CI, 1.26-2.71; P< .001, respectively). The early administration of Gp IIb/IIIa inhibitors was ass ociated with a 28%reduction of mortality from 4.7%to 3.4%, which was not sign ificant but consistent with similar trends for reinfarction and the composite is chemic end point. Conclusions: In a meta-analysis of 6 randomized trials, early administration of Gp IIb/IIIa inhibitors in STEMI appeared to improve coronary patency with favorable trends for clinical outcomes. These findings are supporti ve of a strategy of facilitated PCI. Further evaluations in adequately powered l arge trials are awaited to confirm the clinical benefit of this strategy.展开更多
基金the National Natural Science Foundation of China (No. 39270723).
文摘Objectives: To investigate the relation between metastatic potential of salivary adenoid cystic carcinoma (SACC) and tumor cell-platelet adhesion, and the antimetastatic effect of integrin IIb/IIIa inhibitor on SACC. Methods: Tumor cell-platelet adhesion of highly metastatic SACC-LM, non-highly metastatic SACC-83 and effect of aspirin, arginine-aspartate (RD), magnesium acetylsalicylate on adhesion were studiedin vitro. Antimetastafic effect of aspirin, RD, magnesium acetysalicylate on experimental metastasis of SACC was observedin vivo. Results: The tumor cell-platelet adhesion was stronger in SACC-LM than in SACC-83. Aspirin, RD and magnesium acetylsalicylate could inhibit the adhesion of SACC-LM at the concentration of 1, 5 and 25 μg/ml. RD can inhibit experimental metastasis of SACC. Conclusion: Metastasis of SACC is related to platelet-tumor cell adhesion, RD could inhibit metastasis of SACC.
文摘Objective:To investigate the effect of preoperative bronchial artery infusion chemotherapy on the tumor malignancy of patients with stage IIIA non-small cell lung cancer.Methods:99 patients with stage IIIA non-small cell lung cancer who underwent surgical treatment in our hospital between January 2015 and August 2018 were chosen as the research subjects, and the preoperative adjuvant therapies were reviewed and used to divide them into the control group (n=51) who received conventional neoadjuvant chemotherapy and the study group (n=48) who received neoadjuvant chemotherapy combined with bronchial artery infusion chemotherapy. The differences in the expression levels of NSCLC-related proliferation, invasion and apoptosis genes in intraoperative lesion tissues were compared between the two groups.Results: NSCLC-related proliferation genes CD137L, dlk1, EZH2 and WT1 mRNA expression in lesion tissues of study group were lower than those of control group whereas DCLAK11 mRNA expression was higher than that of control group;NSCLC-related invasion genes ALX1, periostin and RAC1 mRNA expression were lower than those of control group whereas DAL-1 mRNA expression was higher than that of control group;NSCLC-related apoptosis genes Survivin, Livin, bcl-2 and Bag-1 mRNA expression were lower than those of control group.Conclusion: Preoperative bronchial artery infusion chemotherapy can further inhibit the malignant biological behaviors of cancer cells in patients with stage IIIA NSCLC.
文摘Context: Glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibitors improve myocard ial rep erfusion and clinical outcomes of patients undergoing primary percutaneous coron ary intervention (PCI), but optimal timing of administration remains unclear. No systematic reviews have comprehensively examined the effects of early vs delaye d administration of these agents. Objective: To perform a meta-analysis of ra nd omized trials of early (prior to transfer to the catheterization laboratory) vs late (at the time of PCI) intravenous administration of Gp IIb/IIIa inhibitors i n acute ST-segment elevation myocardial infarction (STEMI). Data Sources: MEDLI NE and the Cochrane Controlled Trials Register search of the literature over the past 10 years; papers presented at major cardiac conferences; consultation with national and international colleagues as well as Gp IIb/IIIa inhibitor drug man ufacturers; and text and journal article bibliographies. Study Selection and Dat a Extraction: We examined trials of randomized comparisons between early adminis tration at the point of initial contact (emergency department or ambulance) and late administration (catheterization laboratory) of Gp IIb/IIIa inhibitors in ST EMI. Outcome data had to be available on both culprit artery patency evaluated b y Thrombolysis in Myocardial Infarction (TIMI) flow grades on admission and mort ality. Two authors independently reviewed abstracts or complete articles. Six st udies met inclusion criteria. Independent data extraction was performed by 2 rev iewers and confirmed by consensus. Data Synthesis: The 6 trials enrolled 931 STEMI patients treated with abciximab (3 trials) or tirofiban (3 trials) in combination with primary P CI. TIMI grade 2 or 3 flow (41.7%<<194/465 vs 29.8%<<139/466>>) as well as TIMI g rade 3 flow (20.3%<<84/ 413>> vs 12.2%<<51/418>>) were significantly more frequent in the early group compared with the late group (odds ratio <<OR>>, 1.69; 95%con fidence interval <<CI>>, 1.28-2.22; P< .001; and OR, 1.85; 95%CI, 1.26-2.71; P< .001, respectively). The early administration of Gp IIb/IIIa inhibitors was ass ociated with a 28%reduction of mortality from 4.7%to 3.4%, which was not sign ificant but consistent with similar trends for reinfarction and the composite is chemic end point. Conclusions: In a meta-analysis of 6 randomized trials, early administration of Gp IIb/IIIa inhibitors in STEMI appeared to improve coronary patency with favorable trends for clinical outcomes. These findings are supporti ve of a strategy of facilitated PCI. Further evaluations in adequately powered l arge trials are awaited to confirm the clinical benefit of this strategy.
